Tumor lysate and IL-18 loaded dendritic cells elicits Th1 response, tumor-specific CD8+ cytotoxic T cells in patients with malignant glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2005-04-01 / J. Neurooncol. 2005 Apr;72(2):107-13T-cell triggering by CD3- and CD28-binding molecules linked to a human virus-modified tumor cell vaccine
/in International Publications, Newcastle Disease Virus /von 2005-03-31 / Vaccine 2005 Mar;23(19):2439-53Therapeutic effect of autologous dendritic cell vaccine on patients with chronic hepatitis B: a clinical study
/in Chronic Virus Hepatitis, International Publications /von 2005-03-28 / World J. Gastroenterol. 2005 Mar;11(12):1806-8Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results
/in International Publications, Malignant Melanoma /von 2005-03-18 / Vaccine 2005 Mar;23(17-18):2367-73Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2005-03-11 / Am. J. Respir. Crit. Care Med. 2005 May;171(10):1168-77The large scale generation of dendritic cells for the immunization of patients with non-small cell lung cancer (NSCLC)
/in Dendritic Cells, International Publications, NSCLC /von 2005-03-01 / Lung Cancer 2005 Mar;47(3):337-50Processing and presentation of exogenous HLA class I peptides by dendritic cells from human immunodeficiency virus type 1-infected persons
/in HIV/AIDS, International Publications /von 2005-03-01 / J. Virol. 2005 Mar;79(5):3052-62Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus
/in International Publications, Newcastle Disease Virus /von 2005-03-01 / Cancer Gene Ther. 2005 Mar;12(3):295-303A pilot clinical trial of vaccination with dendritic cells pulsed with autologous tumor cells derived from malignant pleural effusion in patients with late-stage lung carcinoma
/in International Publications, NSCLC /von 2005-02-15 / Cancer 2005 Feb;103(4):763-71IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de